CN Patent

CN113599539A — 治疗甲状腺素运载蛋白（ttr）介导的淀粉样变性的方法

Assigned to Alnylam Pharmaceuticals Inc · Expires 2021-11-05 · 5y expired

What this patent protects

本文披露的是通过给予有效量的甲状腺素运载蛋白(TTR)抑制组合物来减少或阻止人类受试者中的神经病变损伤评分(NIS)或改良的NIS(mNIS+7)增加的方法。

USPTO Abstract

本文披露的是通过给予有效量的甲状腺素运载蛋白(TTR)抑制组合物来减少或阻止人类受试者中的神经病变损伤评分(NIS)或改良的NIS(mNIS+7)增加的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN113599539A
Jurisdiction
CN
Classification
—
Expires
2021-11-05
Drug substance claim
No
Drug product claim
No
Assignee
Alnylam Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.